Brief: Actinium Announces Positive Interim Results From Iomab-B Pivotal Phase 3 Sierra Trial At 50% Of Total Patient Enrollment

Actinium Pharmaceuticals

28/10/2019 12:22

Oct 28 (Reuters) - Actinium Pharmaceuticals Inc  ATNM.A :
    * ACTINIUM ANNOUNCES POSITIVE INTERIM RESULTS FROM IOMAB-B
PIVOTAL
PHASE 3 SIERRA TRIAL AT 50% OF TOTAL PATIENT ENROLLMENT
    * ACTINIUM PHARMACEUTICALS INC - ALL PATIENTS IN STUDY ARM
RECEIVING A THERAPEUTIC DOSE OF IOMAB-B WERE SUCCESSFULLY
TRANSPLANTED
    * ACTINIUM PHARMACEUTICALS INC - HIGH FAILURE RATE OF
CONTROL ARM
IN STUDY WITH 18% COMPLETE REMISSION RATE

Source text for Eikon:  ID:nPn2JgB1Ba 
Further company coverage:  ATNM.A 

 ((Reuters.Briefs@thomsonreuters.com;))